PDS Biotechnology Q1 net loss narrows

PDS Biotechnology

13/05/2026 12:08

Overview

U.S. immunotherapy developer's Q1 net loss narrows yr/yr, adjusted EPS loss improves

Operating expenses fell, mainly due to lower clinical and manufacturing costs

Outlook

Company did not provide specific financial or operational guidance for the current period in press release

Result Drivers

LOWER CLINICAL COSTS - Co said decrease in research and development expenses was primarily due to lower clinical and manufacturing costs

REDUCED ADMINISTRATIVE FEES - Co said general and administrative expenses fell mainly due to lower professional fees

Company press release: ID:nGNX55D1lV

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
Beat
-$0.13
-$0.15 (1 Analyst)
Q1 Net Income
-$7.30 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for PDS Biotechnology Corp is $4.50, about 309.1% above its May 12 closing price of $1.10

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)